F16.288
Hallucinogen dependence with other hallucinogen-induced disorder
Clinical Classification Guidelines
Medical Intelligence & Overview
ICD-10 Code F16.288 refers to a condition characterized by a dependence on hallucinogenic substances accompanied by additional hallucinogen-induced disorders. This diagnosis highlights both the ongoing addictive behavior and the presence of various mental health or behavioral disturbances triggered by hallucinogen use. Hallucinogens are drugs that alter perception, thoughts, and feelings, leading to hallucinations or distorted sensory experiences. Dependence implies a reproducible craving and the development of tolerance or withdrawal symptoms upon cessation. This condition often requires comprehensive clinical attention to address both the reliance on hallucinogens and the associated psychological or behavioral symptoms.
Causes & Symptoms
Clinical Causes: Repeated use of hallucinogenic substances such as LSD, psilocybin, mescaline, or DMT. Genetic predisposition to substance dependence. Environmental factors such as peer influence or stressful life events. Psychological factors like preexisting mental health conditions or trauma. Availability and accessibility of hallucinogenic drugs.
Key Symptoms: Persistent desire or unsuccessful efforts to cut down or control use. Cravings for hallucinogens or compulsive drug-seeking behavior. Tolerance, requiring larger doses for the same effect. Withdrawal symptoms such as agitation, anxiety, or mood swings when not using the drug. Hallucinogen-induced disorders, which may include:
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a comprehensive clinical assessment, including a detailed history of drug use and mental health evaluation. Healthcare providers utilize criteria from the ICD-10 to identify dependence features, such as impaired control, social impairment, risky use, and physiological dependence manifested as tolerance or withdrawal. Additionally, the presence of other hallucinogen-induced disorders must be documented, which may involve symptoms like psychosis, anxiety, mood disturbances, or perceptual abnormalities triggered or exacerbated by hallucinogen use.
Treatment Protocols: Detoxification under medical supervision to manage withdrawal symptoms. Psychotherapy, such as cognitive-behavioral therapy (CBT), to address substance dependence and behavioral patterns. Counseling and support groups to promote recovery and prevent relapse. Pharmacological interventions where appropriate, although specific medications for hallucinogen dependence are limited. Long-term follow-up to monitor mental health and prevent resurgence of substance use.
Clinical Advice & FAQs
Billing Guidance
Is F16.288 a billable ICD-10 code?
Yes, F16.288 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F16.288?
Clinical documentation must specify the nature of Hallucinogen dependence with other hallucinogen-induced disorder and any associated comorbidities for accurate reporting.
Cite this Clinical Reference